(Total Views: 730)
Posted On: 07/07/2021 8:36:57 PM
Post# of 154991
henry f,
"The BLA deficiencies were the result of substandard work by certain prior regulatory consultants. The delays in the resubmission of the BLA are related primarily to the Company’s unexpected pivot to focus on COVID-19 clinical trials, engaging new regulatory consultants to effectively address the noted deficiencies and the limited availability of diagnostics laboratory capacity due to the ongoing COVID-19 pandemic."
Now we know.
It was kind of Current Management to not throw Bruce Patterson and IncellDX under the bus, but what does that get Current Management?
And Thank You Dr. Recknor and Team!!! Finally. A truth-teller.
Chazzle
"The BLA deficiencies were the result of substandard work by certain prior regulatory consultants. The delays in the resubmission of the BLA are related primarily to the Company’s unexpected pivot to focus on COVID-19 clinical trials, engaging new regulatory consultants to effectively address the noted deficiencies and the limited availability of diagnostics laboratory capacity due to the ongoing COVID-19 pandemic."
Now we know.
It was kind of Current Management to not throw Bruce Patterson and IncellDX under the bus, but what does that get Current Management?
And Thank You Dr. Recknor and Team!!! Finally. A truth-teller.
Chazzle
(11)
(0)
